Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668571 · ClinicalTrials.gov registry record · Phase 2
Intravenous Ketamine for Treatment-Resistant Depression
A Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD), sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06668571 is a Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 234-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06668571, a Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD), is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Normal Saline
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06668571
The ClinicalTrials.gov registry entry for NCT06668571 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 234-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depressive Disorder, Treatment-Resistant appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT06668571 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06668571 about?
NCT06668571 is a clinical study titled "Intravenous Ketamine for Treatment-Resistant Depression". The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with ...
What is the current status of trial NCT06668571?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-10. Estimated completion is 2027-12-31.
What conditions does trial NCT06668571 study?
This clinical trial studies the following conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD).
What interventions are being tested in trial NCT06668571?
The interventions under investigation include: Ketamine (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT06668571?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06668571 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Treatment-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Dopaminergic Dysfunction in Late-Life Depression
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
COMPLETED · Phase 2
-
Improving Brain Stimulation Through Imaging
ACTIVE NOT RECRUITING
-
Adaptive tDCS for Treatment-Resistant MDD
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Depressive Disorder, Treatment-Resistant
All registered trials for this condition
Treatment Resistant Depression (TRD)
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.